Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

This article provides a contemporary review and a new perspective on the role of neprilysin
inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Aim Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …

This clinical consensus statement reviews the use of inotropic support in patients with
advanced heart failure. The current guidelines only support use of inotropes in the setting of …

The discovery of the heart as an endocrine organ resulted in a remarkable recognition of the
natriuretic peptide system (NPS). Specifically, research has established the production of …

Background The glucagon-like peptide-1 receptor agonist, semaglutide, improved health
status and reduced body weight in patients with obesity-related heart failure (HF) with …

Introduction: This consensus statement of Australian clinicians provides new
recommendations for the pharmacological management of heart failure based on studies …

Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of
adverse outcomes, even when treated with optimal guideline‐directed medical therapy and …